Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Baird

Nurse Practitioner Cortland, OH Nurse Practitioner

NPI 1801951330 CMS profile 10948782

2249 Elm Road Ext, Cortland, OH 44410

Open in the dashboard

General payments

$14,540

1,123 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Baird of Cortland, OH is reported in the CMS Open Payments database as having received $14,540 across 1,123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,962 243
2024 General $2,911 255
2023 General $3,327 202
2022 General $2,929 209
2021 General $2,409 214

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Baird
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Heather Baird were reported at $2,962. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Heather Baird Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,409 $135 $40–$426 $132
2022 $2,929 $152 $48–$470 $149
2023 $3,327 $166 $54–$529 $160
2024 $2,911 $173 $55–$556 $164
2025 $2,962 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,696 265 payments
  2. Novo Nordisk Inc $1,304 161 payments
  3. Amgen Inc. $1,278 115 payments
  4. Lilly USA, LLC $1,115 94 payments
  5. Pfizer Inc. $957 108 payments
  6. AstraZeneca Pharmaceuticals LP $790 35 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $784 35 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $555 43 payments
  9. GlaxoSmithKline, LLC. $318 21 payments
  10. Otsuka America Pharmaceutical, Inc. $300 26 payments
  11. Other $3,442 220 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,513 1,121 payments
  2. Education $27 2 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,342 103 payments
  2. QULIPTA $1,314 73 payments
  3. VRAYLAR $1,141 73 payments
  4. Ozempic $1,039 130 payments
  5. Otezla $1,006 91 payments
  6. RYBELSUS $838 126 payments
  7. Kerendia $784 35 payments
  8. MOUNJARO $642 50 payments
  9. Repatha $567 56 payments
  10. NURTEC ODT $545 70 payments
  11. Other $10,733 813 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

9,026

Median for Nurse Practitioner: 389

Drug cost

$1,177,785

Median for Nurse Practitioner: $21,885

Branded share of claims

23.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 109 $147,873
Eliquis Apixaban Brand 122 $133,968
Jardiance Empagliflozin Brand 104 $127,872
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 108 $84,618
Mounjaro Tirzepatide Brand 55 $70,355
Xifaxan Rifaximin Brand 19 $66,357
Trulicity Dulaglutide Brand 56 $63,048
Repatha Sureclick Evolocumab Brand 26 $41,518
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 37 $40,125
Xarelto Rivaroxaban Brand 29 $33,755

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$265 — —
Kerendia
$240 — —
Otezla
$180 — —
REXULTI
$167 — —
Veozah
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

1,123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record